Trex Wind-down, Inc. (BPC.F)

0,2920 0,0000 (0,00%) Börsenschluss: 09:23AM CEST

Trex Wind-down, Inc.

3 Mountain View Road
Suite 100
Warren, NJ 07059
United States
973 314 9577
https://www.timberpharma.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 9

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. John Koconis M.B.A.	Chairman, CEO & President	534,58k	N/A	1971
Mr. Joseph Lucchese	Executive VP, CFO, Treasurer & Secretary	508,43k	N/A	1968
Dr. Alan Mendelsohn M.D.	Executive VP & Chief Medical Officer	475,48k	N/A	1964

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. On November 17, 2023, Timber Pharmaceuticals, Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Corporate Governance

Trex Wind-down, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.